Key facts
- It has raised $7.0M; the latest was Seed Round ($7.0M) in May 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for ImmuneWalk Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ImmuneWalk Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmuneWalk Therapeutics
Operator of a biotechnology company intended to specialize in the development of novel therapies for chronic inflammatory diseases. The company specializes in the development of anti-inflammatory agents such as monoclonal antibodies that are engineered to specifically prevent monocytes from exiting the bloodstream and traveling to inflammatory sites, enabling medical practitioners to treat patients with inflammatory indications.
- Sector
- Healthcare
- HQ
- Pearl River, NY, United States
- Founded
- 2023
- Employees
- 7
- Website
- immunewalk.com/
- Ownership
- Privately Held (backing)
ImmuneWalk Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmuneWalk Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmuneWalk Therapeutics in its N-PORT filings yet. We sweep new filings monthly.